Kraig Biocraft Laboratories Inc (KBLB)

[arachnodude]

Your scare tactics around dilution conveniently ignore the broader context of how and why companies like KBLB use it. Dilution isn’t inherently bad—especially when the funds raised are used to fuel growth, expand operations, and ultimately drive the company towards profitability. The fact that the share price fluctuates after dilution is par for the course in any growth-stage company. What matters is how the company uses those funds to build long-term value.

Warren Buffett knows that every situation is unique. KBLB is not some fly-by-night operation ‘hell-bent’ on issuing shares for the sake of it. They’re raising capital to advance the commercialization of a groundbreaking technology—spider silk—something that requires significant investment to scale properly. The short-term fluctuations in share price are a necessary part of that journey.

And let’s be real: Warren Buffett’s investment strategies are centered around mature, cash-flow-positive companies. KBLB, on the other hand, is a high-growth, high-potential biotech company in the midst of developing and scaling a revolutionary product. Comparing the two is like comparing apples to oranges.

Your focus on past price drops is nothing more than fearmongering. The real question is: what will KBLB achieve with the capital raised through dilution? That capital is being used effectively, and it's positioning KBLB to capture significant market share in a completely new industry. Long-term investors understand this, and they’re not swayed by short-term dips driven by fear.

So before you throw around Warren Buffett quotes, maybe consider the full picture. KBLB is raising capital to fund a future that has the potential to redefine multiple industries. That’s not ‘hell-bent dilution’—that’s strategic growth!